PGP and gastric cancer: Further studies confirmed that TRAIL (5 ng/ml), Bay (5 μM), or combined treatment promoted the expression of cleaved-caspase-8/3, but inhibited the expression of P-gp in drug-resistant gastric cancer cells SGC7901/DDP and BGC823/DDP (Fig. 3aiii, biii), as compared with normal cells.